Owkin uses AI to find the right treatment for every patient
We combine the best of human and artificial intelligence to discover and develop new and better drugs at scale.
We bridge shared innovation challenges between biopharma and academic researchers and close the translational gap between complex biology and new drugs.
Everything starts with patient data
Owkin has a new way of seeing the patient and their disease. We subtype patients with distinct biology to find patterns in disease mechanisms which could lead to novel targets and therapies.
Federated Data Network
Substra powers our federated data network giving us access to rich, multimodal patient data to run our internal R&D and help deliver biopharma projects. The technology platform we are developing will be a collaboration zone that connects top academic researchers and data scientists to maximize the value of their data.
Biomarkers & subgroups
We apply AI to multimodal, KOL-defined data to subtype patients and identify novel biomarkers to inform drug discovery, de-risk clinical trials and develop and deploy diagnostics in clinical practice.
Drug discovery
Our drug discovery engines combine our expertise in AI, biology and medicine to fully understand the disease patterns and complex biological interactions defining specific patient subgroups. Our models identify and rank genes and proteins to discover novel targets, pathways, indications, drugs and combinations.
Pre-clinical development
Owkin is establishing partnerships to develop these capabilities.
Clinical development
Our machine learning methodologies de-risk and accelerate clinical trials using patient data and innovative modalities.
Diagnostics
Our solutions help pre-screen for biomarkers, and predict outcomes— giving healthcare providers a fuller picture of a patient’s disease. This means more patients can benefit from targeted therapies, making precision medicine more accessible to more patients at an earlier stage of their disease.













Hear from our partners
Join the conversation
Join the conversation

Nature Medicine publishes breakthrough Owkin research on the first ever use of federated learning to train deep learning models on multiple hospitals’ histopathology data
Read the press release
Visit Owkin at booth 363 at USCAP 2023 (March 11-16, 2023) to learn about our digital pathology AI diagnostic solutions designed to directly improve patient outcomes.
Set up a meeting with usTake a closer look